Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Senate Health and Welfare hears bill to let treasurer join ArrayRx prescription discount card
Loading...
Summary
The Senate Health and Welfare committee reviewed H.577, which would authorize the state treasurer to join the ArrayRx multistate prescription drug discount-card program, appropriate $50,000 for outreach, require implementation and annual reports, and mandate insurers/PBMs accept proof-of-payment so card purchases count toward deductibles.
The Senate Health and Welfare committee on April 10 heard H.577, a bill that would authorize the Vermont office of the state treasurer to join ArrayRx, a multistate consortium offering a prescription drug discount card that officials said could lower out-of-pocket costs for Vermonters.
Representative Critchlow introduced the measure to the committee, saying the program would let “any Vermont resident” enroll in a discount-card program administered through a multistate collaboration. Critchlow said the card can yield steep savings in many cases and noted Medicare’s recent participation nationally: “residents have seen an average savings of approximately $259 a month,” she said, and the bill would be self-funded through a small transaction fee baked into advertised prices rather than by ongoing state general-fund support.
Jan Harvey of the Office of Legislative Council walked the committee through the bill text, noting the bill would create a new subchapter in the prescription drug cost-containment statutes to establish the Vermont prescription drug discount card program administered by the treasurer. Harvey said the bill directs that monies received by the program be deposited into an existing special fund (renamed the Financial Literacy and Economic Empowerment Trust Fund) to defray administration costs, requires a treasurer implementation report by Jan. 15, 2027, and starts annual reporting on program participation and savings on Jan. 15, 2028. Section 5 would appropriate $50,000 from the general fund in fiscal 2027 to develop and implement the program; the act would take effect July 1.
Peter Cromley, presenting for the treasurer’s office, described ArrayRx as a long-running state collaborative administered out of Oregon that negotiates discount prices and operates customer service and IT for participating states. He said the card requires no enrollment fee for Vermonters, covers all FDA-approved prescription drugs and certain over-the-counter items, and lets consumers look up participating pharmacies and prices ahead of purchase. “All FDA approved prescription drugs and a number of over the counter items have a discount on this card,” Cromley told the committee.
Cromley and representatives said the consortium collects anonymized state-level data for program monitoring and that personal customer data would not be sold to brokers through ArrayRx. Committee members raised privacy concerns; one member said retail pharmacies currently “are selling it to data miners,” and Cromley replied the ArrayRx model restricts access to participating states and does not sell customer data.
The bill also adds statutory language to make amounts paid using a discount card count toward a covered person’s deductible and out-of-pocket maximums under their health plan, while requiring insurers and pharmacy benefit managers to provide a downloadable proof-of-payment form or other mechanisms so members can demonstrate those payments to their insurers. Legislative counsel said those provisions clarify existing co-pay accumulator rules and add the discount-card mechanism to existing consumer-protection language.
Committee members questioned how ArrayRx prices are produced and whether pharmacy margins or pharmacy benefit managers (PBMs) are affected. Cromley described the consortium’s market leverage in negotiating pricing options and said the program’s operating costs are covered by a small fee included in the advertised price; any leftover revenue is returned to states proportionally. He also acknowledged some independent pharmacists have expressed concern that certain transactions could reduce margins, while other independent pharmacists and pharmacy associations have sent letters of support.
On uptake and outreach, Cromley said the treasurer’s office requested $50,000 to fund paid media and other outreach because enrollment numbers determine program impact. He cited Connecticut’s experience, where Cromley said the state initially funded the program without marketing and saw under 1% enrollment; Vermont’s proposal includes an upfront outreach appropriation to avoid similar low uptake. The treasurer’s office told the committee it hopes to complete contracting promptly and aims to launch the program by the end of the year or very early next year, subject to contracting timelines.
Representative Critchlow and Cromley provided different aggregate-savings framings to illustrate potential benefits: Cromley estimated Vermont could save about $20 million a year if 1% of Vermonters signed up and saw Connecticut-like savings; earlier in the hearing a witness cited a larger hypothetical aggregate figure tied to other assumptions. The committee did not vote on H.577 during the session; presenters answered questions and the panel moved on to another agenda item after a brief recess.
The bill’s statutory language, the appropriation request, the treasurer’s implementation timeline and the annual-reporting requirements are all included in the draft presented to the committee. The committee will consider the treasurer’s office follow-up materials and written letters from pharmacies and advocacy groups as it decides whether to advance the bill.
